General Surgery and Liver Transplantation Unit, Azienda Ospedaliero-Universitaria Pisana, Ospedale Cisanello, Pisa, Italy.
Clin Transplant. 2009 Nov-Dec;23(6):853-60. doi: 10.1111/j.1399-0012.2009.00957.x. Epub 2009 Jan 30.
The aim of the present work was to assess the incidence of neuro-nephrotoxicity after a single-staggered dose of calcineurin inhibitors (CI) with different immunosuppressive approaches. From January to December 2006, all liver transplantation (LT) recipients at risk of renal or neurological complications treated with extracorporeal photopheresis (ECP) + mycophenolate mofetil + steroids and staggered introduction of CI (ECP group) were compared with a historical control group on standard CI-based immunosuppression. The ECP group included 24 patients with a mean model for end-stage liver disease (MELD) score of 19.9 +/- 11.1. The control group consisted of 18 patients with a mean MELD score of 12.5 +/- 5.2 (p = 0.012). In the ECP group CI were introduced at a mean of 9.2 +/- 6.2 d (4-31 d) after LT. Five patients in the ECP group presented acute neuro-nephrotoxicity after the first CI administration on post-transplant d 4, 5, 6, 6, and 14. Overall patient survival at one, six, and 12 months was 100%, 95.8%, and 95.8% in the ECP group vs. 94.4%, 77.7%, and 72.2% in the control group (p < 0.001). In conclusion, we showed that CI toxicity may occur after a single-staggered dose administration, ECP seems to be a valuable tool for managing CI-related morbidity regardless of the concomitant immunosuppressive regimen, being associated with a lower mortality rate in the early post-transplant course.
本研究旨在评估单次不同免疫抑制方案下使用钙调磷酸酶抑制剂(CNI)后神经肾毒性的发生率。2006 年 1 月至 12 月,所有有发生肾或神经并发症风险的肝移植(LT)患者,采用体外光化学疗法(ECP)+吗替麦考酚酯+类固醇,且 CNI 采用分期引入法,与标准基于 CNI 的免疫抑制方案下的历史对照患者(ECP 组)进行比较。ECP 组有 24 名患者,平均终末期肝病模型(MELD)评分为 19.9+/-11.1。对照组有 18 名患者,平均 MELD 评分为 12.5+/-5.2(p=0.012)。ECP 组在 LT 后平均 9.2+/-6.2d(4-31d)引入 CNI。ECP 组有 5 名患者在 LT 后第 4、5、6、6 和 14 天首次接受 CNI 治疗后出现急性神经肾毒性。ECP 组患者 1、6 和 12 个月的总生存率为 100%、95.8%和 95.8%,对照组分别为 94.4%、77.7%和 72.2%(p<0.001)。总之,我们表明,单次分期给药后可能会发生 CNI 毒性,ECP 似乎是一种管理 CNI 相关发病率的有价值的工具,无论同时采用何种免疫抑制方案,都与 LT 后早期死亡率降低有关。